Ernesto Wasserman

Tellus Institute — United States

Medicine · Health Sciences

20h-index2.3kcitations64works39.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(21), Monoclonal and Polyclonal Antibodies Research(17), Lung Cancer Treatments and Mutations(10), Cancer Treatment and Pharmacology(10), Colorectal Cancer Treatments and Studies(9)

Publications64 total

Abstract A102: Zenocutuzumab efficacy and safety in advanced NRG1+ cholangiocarcinoma: Analysis from the phase 2 eNRGy Trial
Molecular Cancer Therapeutics·2025
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive Cancer
New England Journal of Medicine·2025· 78 citedOpen Access
1618P Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Annals of Oncology·2023· 14 citedOpen Access
Abstract CT012: Clinical activity of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell cancer (HNSCC)
Cancer Research·2023· 10 cited
Abstract CT156: MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced gastric/esophageal adenocarcinoma (GEA)
Cancer Research·2023· 2 cited
Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Data from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Supplementary Table from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Supplementary Figure from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Data from Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by &lt;i&gt;NRG1&lt;/i&gt; Gene Rearrangements
2023Open Access
Supplementary Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Studies of CBP501, a G&lt;sub&gt;2&lt;/sub&gt; Checkpoint Abrogator, as Monotherapy and in Combination with Cisplatin in Patients with Advanced Solid Tumors
2023Open Access
Sustained Tumor Regression With Zenocutuzumab, a Bispecific Antibody Targeting Human Epidermal Growth Factor Receptor 2/Human Epidermal Growth Factor Receptor 3 Signaling, in <i>NRG1</i> Fusion–Positive, Estrogen Receptor–Positive Breast Cancer After Progression on a Cyclin-Dependent Kinase 4/6 Inhibitor
JCO Precision Oncology·2022· 8 citedOpen Access
Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers.
Journal of Clinical Oncology·2022· 65 cited
Abstract OT2-15-01: Updated analysis of MCLA-128 (zenocutuzumab), trastuzumab, and vinorelbine in patients (pts) with HER2 positive/amplified (HER2+) metastatic breast cancer (MBC) who progressed on previous anti-HER2 ADCs
Cancer Research·2022· 6 cited
page 1 of 4Next →

Frequent Co-authors

Alison M. Schram(10), Eileen M. O’Reilly(10), Alexander Drilon(10), Viktoriya Stalbovskaya(9), Esteban Cvitkovic(8), Daniel D. Von Hoff(6), Mitesh J. Borad(6), François Goldwasser(6), Teresa Macarulla(6), Jordi Rodón(6), M. Duruisseaux(6), Andrew K. Joe(6), Geoffrey I. Shapiro(6), Cristian Fernández(5), William Sutherland(5), Reinhard Dummer(5), Dirk Schadendorf(5), Paolo A. Ascierto(5), James Ford(5), Marine Weill(5)